• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

Polar Capital Biotechnology I Income Hedged

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund Provider Polar Capital LLP
Fund Summary The Polar Capital Biotechnology Fund aims to preserve capital and achieve long term capital appreciation by investing in the shares of biothechnology, daignostics and life sciences tools companies. Managed by an experienced fund manager with a strong track record.
SEDOL code BFX4HX5
ISIN IE00BFX4HX56
Fund code POBIH
Managers David Pinniger
Manager Tenure 7 years
Morningstar Category Other Equity
IMA Sector Specialist
Fund Size £560 million
Fund Type OEIC
Management Style Active
Ongoing Charge Figure (OCF) 1.21%
Cavendish ongoing charge 0.05%
FundsNetwork Service Fee 0.20%
Minimum Initial Investment £25
Minimum Top Up £25
Minimum Monthly Investment £25
Sell Price £13.0600
Buy Price £13.0600
Price Change +0.694%
Price Date 2nd June 2020
Yield Currently unavailable
Dividend Frequency Yearly
ISA Eligible Yes
SIPP Eligible Yes
Inception Date 3rd September 2018
Fund Status OPEN
David Pinniger joined Polar Capital in August 2013 as lead manager of the Biotechnology Fund within the healthcare team. Prior to joining Polar Capital, for five years David was portfolio manager of the International Biotechnology Trust at SV Life Sciences. He also previously spent three years working at venture capital firm Abingworth as an analyst managing biotechnology investments held across the firm’s venture and specialist funds, and four years at Morgan Stanley as an analyst covering the European pharmaceuticals and biotechnology sector. David received a first class honours degree in human sciences from Oxford University in 1999 and is a CFA charterholder.

3-year Mean Monthly Return: Currently unavailable

Annual Returns 2019 2018
Fund Performance -6.64% +4.80%
Benchmark Performance
(Other Equity)
Time Period Cumulative Benchmark Performance
(Other Equity)
Fund Compared to Benchmark
1 day 0.69% Currently unavailable Currently unavailable
1 week 3.40% Currently unavailable Currently unavailable
1 month 13.07% Currently unavailable Currently unavailable
3 months 16.19% Currently unavailable Currently unavailable
6 months 21.15% Currently unavailable Currently unavailable
1 year 33.27% Currently unavailable Currently unavailable
3 years Currently unavailable Currently unavailable Currently unavailable
5 years Currently unavailable Currently unavailable Currently unavailable
10 years Currently unavailable Currently unavailable Currently unavailable
YTD 12.01% Currently unavailable Currently unavailable
Since inception 11.95% Currently unavailable Currently unavailable

Top 10 shares for this fund

Share Name Country Value
Incyte Corp USA 5.82%
Vertex Pharmaceuticals Inc USA 5.35%
Alexion Pharmaceuticals Inc USA 5.04%
Seattle Genetics Inc USA 4.68%
NanoString Technologies Inc USA 4.06%
Alnylam Pharmaceuticals Inc USA 3.37%
Exelixis Inc USA 2.95%
uniQure NV NLD 2.71%
Biohaven Pharmaceutical Holding Co Ltd USA 2.61%
argenx SE NLD 2.57%

Currently unavailable